Skip to content
Screener

Omeros OMER Debt-to-equity

Discontinued — last reported Q4 '22

Debt-to-equity at other companies

Immunome logo
ImmunomeIMNM
0×0.0×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
0×0.0×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
0.1×-7.2×
Annexon logo
AnnexonANNX
0.1×0.0×
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
0×0.0×
Vor Biopharma logo
Vor BiopharmaVOR
0.5×+0.2×

Other financials

Income statement

See full
Revenue$9.9M—
Gross profit$29.7M—
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$958.97M+245%
P/S10.7×—

Profitability

See full
Gross margin98.9%—
Operating margin-181.8%—
Net margin-136.6%—
FCF margin-121.6%—

Returns & leverage

See full
Return on equity86.6%—
Current ratio3×+1.9×

Where this comes from

Calculated from Omeros’s reported figures.

total debt/total stockholders equity=0.3×

Based on the most recent quarter.

The source filing: Omeros’s 10-Q, filed August 9, 2023. Open the filing →

Filed
Aug 9, 2023
Fiscal quarter
Q2 FY2023
Calendar quarter
Q2 2023
Accession
0001558370-23-014095

FAQ

What is Omeros's debt-to-equity?
Omeros (OMER) reported debt-to-equity of 0.3× in Q4 2022.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Omeros's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude